Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Hong Zebger‐Gong"'
Autor:
Yasong Lu, Shuang Liang, Ying Hong, Naoyuki Tajima, Kashyap Patel, Hanbin Li, David R. Wada, Jon Greenberg, Adam Petrich, Hong Zebger‐Gong, Dale Shuster, Pavan Vaddady
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 1, Pp 23-28 (2024)
Abstract To replace the conventional maximum tolerated dose (MTD) approach, a paradigm for dose optimization and dose selection that relies on model‐informed drug development (MIDD) approaches has been proposed in oncology. Here, we report our appl
Externí odkaz:
https://doaj.org/article/07375fb147c347daba609e818c44fe7c
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101917- (2023)
Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with mic
Externí odkaz:
https://doaj.org/article/607bb200b67a4b90be60f4ef3e49d300
Autor:
Funda Meric-Bernstam, Ian Krop, Dejan Juric, Takahiro Kogawa, Erika Hamilton, Alexander I. Spira, Toru Mukohara, Takuya Tsunoda, Senthil Damodaran, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Hong Zebger-Gong, Yui Kawasaki, Rie Wong, Aditya Bardia
Publikováno v:
Cancer Research. 83:PD13-08
Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1 monoclonal antibody covalently linked to a highly potent topoisomerase I (Topo I) inhibitor payload via a stable, tumor-select
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5e79b5891a3d5783a55480302672bb9
https://doi.org/10.1158/1538-7445.sabcs22-pd13-08
https://doi.org/10.1158/1538-7445.sabcs22-pd13-08
Autor:
Aditya Bardia, Ian Krop, Funda Meric-Bernstam, Anthony W. Tolcher, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Erika Hamilton, Alexander I. Spira, Kyriakos P. Papadopoulos, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Hong Zebger-Gong, Yui Kawasaki, Rie Wong, Takahiro Kogawa
Publikováno v:
Cancer Research. 83:P6-10
Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1 mAb covalently linked to a highly potent topoisomerase I (Topo I) inhibitor payload via a stable, tumor selective, tetrapeptid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1880b8ce0aa7ca0ab52c94818032ace
https://doi.org/10.1158/1538-7445.sabcs22-p6-10-03
https://doi.org/10.1158/1538-7445.sabcs22-p6-10-03
Autor:
Sabine Fiala-Buskies, Kirhan Ozgurdal, Catherine Frenette, H.Y. Lim, S. Qin, Yoon Jun Kim, Richard S. Finn, Gianluca Masi, Masatoshi Kudo, Hong Zebger-Gong, Masafumi Ikeda, René Gerolami, Philippe Merle, Kazushi Numata, H.-J. Klümpen, Masayuki Kurosaki
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2020, 31, pp.S699-S700. ⟨10.1016/j.annonc.2020.08.1126⟩
Annals of Oncology, Elsevier, 2020, 31, pp.S699-S700. ⟨10.1016/j.annonc.2020.08.1126⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3859364ba3b744d29cc62b16ccbf93
https://hal-amu.archives-ouvertes.fr/hal-03161166
https://hal-amu.archives-ouvertes.fr/hal-03161166
Autor:
William P. Harris, Max W. Sung, Dirk Waldschmidt, Ying A. Wang, Tatiane Cristine Ishida, Richard D. Kim, Udo Mueller, Barbara J. Brennan, Vittorio Luigi Garosi, Hong Zebger-Gong, Peter R. Galle, Anthony B. El-Khoueiry, Roniel Cabrera
Publikováno v:
Journal of Clinical Oncology. 39:4078-4078
4078 Background: REG, a multikinase inhibitor, and PEMBRO, an anti-PD-1 mAb, are approved as monotherapies in advanced HCC after progression on sorafenib. This phase 1b dose-finding study investigated first-line REG plus PEMBRO in advanced HCC. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc3fd045a213221bdbb1ffc8b13fd002
https://doi.org/10.1200/jco.2021.39.15_suppl.4078
https://doi.org/10.1200/jco.2021.39.15_suppl.4078
Autor:
Kirhan Ozgurdal, Masafumi Ikeda, Philippe Merle, Masayuki Kurosaki, Shukui Qin, Catherine Frenette, Heinz-Josef Klümpen, Richard S. Finn, Yoon Jun Kim, René Gerolami, Sabine Fiala-Buskies, Ho Yeong Lim, Gianluca Masi, Hong Zebger-Gong, Kazushi Numata, Masatoshi Kudo
Publikováno v:
Journal of Clinical Oncology. 38:e16680-e16680
e16680 Background: REG is approved for the treatment of pts with HCC who previously received SOR, based on results of the phase 3 RESORCE trial. The REFINE study was designed to evaluate the safety and effectiveness of REG in pts with HCC in real-wor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4465f4493c9a39a860ff928c3f961f35
https://doi.org/10.1200/jco.2020.38.15_suppl.e16680
https://doi.org/10.1200/jco.2020.38.15_suppl.e16680
Autor:
Nadège Corradini, Michela Casanova, Hong Zebger-Gong, Arnauld Verschuur, Bart Ploeger, Adela Cañete, Udo Mueller, Lynley V. Marshall, Francisco Bautista, John Chung, Quentin Campbell Hewson, Birgit Geoerger, Guy Makin
Publikováno v:
Journal of Clinical Oncology. 38:10507-10507
10507 Background: In pediatric patients with solid tumors, regorafenib demonstrated acceptable tolerability and preliminary anti-tumor activity. This phase 1 study evaluated regorafenib in combination with vincristine/irinotecan in pediatric patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9610b09136d9c68166fae64e455d7d8
https://doi.org/10.1200/jco.2020.38.15_suppl.10507
https://doi.org/10.1200/jco.2020.38.15_suppl.10507
Autor:
Ho Yeong Lim, Masatoshi Kudo, Richard S. Finn, Catherine Frenette, Shukui Qin, Kirhan Ozgurdal, Hong Zebger-Gong, Sabine Fiala-Buskies, Masafumi Ikeda, Philippe Merle, Gianluca Masi
Publikováno v:
Journal of Clinical Oncology. 38:542-542
542 Background: Regorafenib significantly improved overall survival (OS) versus placebo in patients (pts) with uHCC who progressed on prior sorafenib therapy in the phase 3 RESORCE trial. The multicenter, international REFINE trial was designed to ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e4e555235be5f3c504b5e2c8a341b72
https://doi.org/10.1200/jco.2020.38.4_suppl.542
https://doi.org/10.1200/jco.2020.38.4_suppl.542
Autor:
Linghua Kong, Jan Kampmann, Jan Roigas, Uwe Hoff, Duska Dragun, Harm Peters, Uwe Querfeld, Kerstin Sommer, Hong Zebger-Gong, Stephanie Krämer, Dominik N. Müller
Publikováno v:
Transplantation. 89:518-526
Background. Occlusive vascular changes, characterized by the formation of a neointima with lumen obstruction, are key histologic findings of allograft arteriosclerosis. Vascular integrity of the graft is critically dependent on nitric oxide (NO), syn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a26d89f842d0e5d88da662edc16807d
https://doi.org/10.1097/tp.0b013e3181c7dce4
https://doi.org/10.1097/tp.0b013e3181c7dce4